Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction to: Comparative Effectiveness and Durability of Biologics in Clinical Practice: Month 12 Outcomes from the International, Observational Psoriasis Study of Health Outcomes (PSoHO).
Pinter A, Costanzo A, Khattri S, Smith SD, Carrascosa JM, Tada Y, Riedl E, Reich A, Brnabic A, Haustrup N, Lampropoulou A, Lipkovich I, Kadziola Z, Paul C, Schuster C. Pinter A, et al. Among authors: kadziola z. Dermatol Ther (Heidelb). 2024 May 30. doi: 10.1007/s13555-024-01105-3. Online ahead of print. Dermatol Ther (Heidelb). 2024. PMID: 38814435 No abstract available.
Incidence of type 2 diabetes, cardiovascular disease and chronic kidney disease in patients with multiple sclerosis initiating disease-modifying therapies: Retrospective cohort study using a frequentist model averaging statistical framework.
Brnabic AJM, Curtis SE, Johnston JA, Lo A, Zagar AJ, Lipkovich I, Kadziola Z, Murray MH, Ryan T. Brnabic AJM, et al. Among authors: kadziola z. PLoS One. 2024 Mar 22;19(3):e0300708. doi: 10.1371/journal.pone.0300708. eCollection 2024. PLoS One. 2024. PMID: 38517926 Free PMC article.
Comparative Effectiveness and Durability of Biologics in Clinical Practice: Month 12 Outcomes from the International, Observational Psoriasis Study of Health Outcomes (PSoHO).
Pinter A, Costanzo A, Khattri S, Smith SD, Carrascosa JM, Tada Y, Riedl E, Reich A, Brnabic A, Haustrup N, Lampropoulou A, Lipkovich I, Kadziola Z, Paul C, Schuster C. Pinter A, et al. Among authors: kadziola z. Dermatol Ther (Heidelb). 2023 Dec 19. doi: 10.1007/s13555-023-01086-9. Online ahead of print. Dermatol Ther (Heidelb). 2023. PMID: 38113010
Type 2 diabetes pharmacotherapy trends in high-risk subgroups.
Bae J, Liu D, Chinthammit C, Kadziola Z, Boye K, Mather K. Bae J, et al. Among authors: kadziola z. Diabetes Obes Metab. 2022 Jun;24(6):1166-1171. doi: 10.1111/dom.14678. Epub 2022 Mar 22. Diabetes Obes Metab. 2022. PMID: 35243741 Free PMC article.
Multilevel network meta-regression for population-adjusted treatment comparisons.
Phillippo DM, Dias S, Ades AE, Belger M, Brnabic A, Schacht A, Saure D, Kadziola Z, Welton NJ. Phillippo DM, et al. Among authors: kadziola z. J R Stat Soc Ser A Stat Soc. 2020 Jun;183(3):1189-1210. doi: 10.1111/rssa.12579. Epub 2020 Jun 7. J R Stat Soc Ser A Stat Soc. 2020. PMID: 32684669 Free PMC article.
Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison.
Fautrel B, Zhu B, Taylor PC, van de Laar M, Emery P, De Leonardis F, Kannowski CL, Nicolay C, Kadziola Z, De La Torre I, Fleischmann R. Fautrel B, et al. Among authors: kadziola z. RMD Open. 2020 Apr;6(1):e001131. doi: 10.1136/rmdopen-2019-001131. RMD Open. 2020. PMID: 32371431 Free PMC article.
55 results